FIELD: biotechnology.
SUBSTANCE: invention relates to immunostimulating protein structures based on CD154, and can be used in medicine for treating diseases, associated with immunity, autoimmune diseases, allergies, lymphoproliferative diseases and cancer, infectious and inflammatory diseases. Disclosed is a nucleic acid (NA) encoding CD154 based transmembrane protein, wherein the NA does not contain a sequence able to encode neither an intracellular portion of CD154, nor an intracellular portion of CD40. Plasmid or viral genetic carrier is also disclosed, containing said NA to express immunostimulant CD40 binding protein, and protein itself for use in therapy.
EFFECT: invention enables to obtain a therapeutically active protein which is trimerised, retained in a plasma membrane and maintains the immunostimulating capacity of CD154.
20 cl, 23 dwg, 2 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
